The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and/or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.

Novel phosphorescent tetradentate platinum compounds of Formula I are provided. The complexes contain a dibenzo moiety, which allows for the creation of OLED devices with improved properties when compounds of Formula I are incorporated into such devices. Compounds of Formula I that comprise two ligands that contain a 5-membered carbocyclic or heterocyclic ring, one of which contains an imidazole ring with a twisted aryl group attached to N1 and a second aromatic ring that is attached to the platinum via a carbon atom. These compounds may be advantageously used in OLEDs.

Disclosed herein are compounds, compositions, and methods for separating platinum halide dianions, such as [PtCl.sub.6].sup.2?, with a cubcurbituril, such as cucurbit[6]uril, is disclosed herein.

In one aspect, phosphine compounds comprising three adamantyl moieties (PAd.sub.3) and associated synthetic routes are described herein. Each adamantyl moiety may be the same or different. For example, each adamantyl moiety (Ad) attached to the phosphorus atom can be independently selected from the group consisting of adamantane, diamantane, triamantane and derivatives thereof. Transition metal complexes comprising PAd.sub.3 ligands are also provided for catalytic synthesis including catalytic cross-coupling reactions.

Metal coordination complexes comprising at least one diazabutadiene based ligand having a structure represented by:

##STR00001## where A.sub.1, A.sub.2, A.sub.3, and A.sub.4 are atoms in a 6-membered ring and are independently selected from C, N, O, S, and P; and where R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6 are independently selected from the group consisting of H, amino groups, C1-C6 alkyl groups, or C4-10 cycloalkyl groups; and further provided that alkyl groups may optionally contain silicon; and where the metal coordination complex is capable of participating in a Diels-Alder type reaction with a dienophile. Processing methods using the metal coordination complexes are also described.

Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

The present disclosure provides an organometallic compound below and an organic light emitting diode and an organic light emitting display device including the organometallic compound. ##STR00001##

The present invention pertains to a method of treating cancer or its relapse in mammals by employing platinum based compounds. More particularly, the present invention provides to enhance immunity in a mammal, using a compound of Formula I and/or Formula II, preferably Compound 1 or its derivative, salt, tautomeric form, isomer, polymorph, solvate, or intermediates thereof. The method of inducing an immune response in a mammal is mediated through immune memory. The present invention also provides for such platinum based compounds and their use in treating cancer, metastasis or cancer relapse.

The compound of the formula (1) and its complexes with metal cations are used for catalysis in hydroformylation processes.

##STR00001##

Provided is a composition A that includes: a first dopant; and a first host; where the first dopant has a HOMO energy HOMODopant and a LUMO energy LUMODopant; the first host has a HOMO energy HOMOHost and a LUMO energy LUMOHost; |LUMOHostHOMODopant|=X1; |LUMODopantHOMOHost|=X2; the first dopant has an optical bandgap energy, Y; at least one of X1 and X2 is less than or equal to Y+0.026 eV; the composition A has a vertical dipole ratio VDR(A); composition B is a reference composition comprising the first dopant and a second host, wherein the second host is

##STR00001##

the composition B having a vertical dipole ratio VDR(B); the ratio of the first dopant and the first host in the composition A is identical to the ratio of the first dopant and second host in the composition B; and VDR(A)VDR(B) is 0.05.